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Immunosuppressive therapy 
in dermatology and PML
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Kim Papp, Georg Stingl
Progressive multifocal leukoencephalopathy (PML) is a rare, demyelinating disease of
the central nervous system that usually leads to death or severe disability. Affected pa-
tients present with signs and symptoms including impaired cognition, visual distur-
bances, hemiparesis, altered mental state and behavioural changes. PML is caused by
activation of the John Cunningham (JC) virus. JC virus resides in latent form in up
to 80 percent of adults. Reactivation of JC virus occurs in immunocompromised pa-
tients. The factors leading to activation of the latent infection are not fully under-
stood. The diagnosis of PML is established based on a detailed medical history, phy-
sical examination, suggestive MRI findings and the presence of the JC virus detected
in the cerebrospinal fluid by PCR. PML has been reported in the published literature
in HIV-positive patients, as well as in patients receiving immunosuppressive agents
because of organ transplantation, cancer or autoimmune diseases. PML has been re-
ported in patients receiving classical immunosuppressive drugs or biologics or both
[1]. There are no known interventions that can prevent or treat PML successfully. 
Recently, two confirmed cases of PML have been reported in US patients receiving
efalizumab (Raptiva
®) for chronic plaque psoriasis [2]. One male patient (age 70) and
one female patient (age 73) had received efalizumab for 4 and 3.8 years, respectively.
These are the first confirmed cases of PML in psoriasis patients receiving immuno-
suppressive therapy. Today, the global exposure of patients on efalizumab is 47,000
patient-years.
Until more information is available and further guidance is received from the health
authorities, a group of independent expert dermatologists advise to strictly follow the
Summary of Product Characteristics of efalizumab [3]. Dermatologists should carefully
weigh risks and benefits in patients during long-term therapy with efalizumab and par-
ticularly in those of advanced age or with a history of immunosuppressive therapy.
In patients receiving any immunosuppressive therapy, dermatologists should be vigi-
lant for signs and symptoms suggestive of PML. Suspicious cases should be referred
to a neurologist.
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